Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TNGX

Tango Therapeutics Inc

Dec 13 • 04:00PM ET

3.06

Dollar change +0.21
Percentage change 7.37	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM KRYS PLRX EDIT SGMO FDMT AFMD VCNX

| Held by: VTI VXF IWM XBI IWO VTWO IBB SCHA VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.17	Insider Own	53.90%	Shs Outstand	107.41M	Perf Week	-9.60%
Market Cap	352.92M	Forward P/E	-	EPS next Y	-1.43	Insider Trans	-14.53%	Shs Float	49.52M	Perf Month	-14.04%
Income	-123.39M	PEG	-	EPS next Q	-0.34	Inst Own	48.07%	Short Float	14.58%	Perf Quarter	-68.16%
Sales	43.38M	P/S	8.14	EPS this Y	-11.20%	Inst Trans	-5.87%	Short Ratio	3.91	Perf Half Y	-65.73%
Book/sh	2.13	P/B	1.43	EPS next Y	-18.65%	ROA	-31.62%	Short Interest	7.22M	Perf Year	-69.40%
Cash/sh	2.54	P/C	1.20	EPS next 5Y	-	ROE	-48.80%	52W Range	2.70 - 13.01	Perf YTD	-69.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-46.75%	52W High	-76.47%	Beta	0.77
Dividend TTM	-	Quick Ratio	8.00	Sales past 5Y	132.62%	Gross Margin	94.25%	52W Low	13.33%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	8.00	EPS Y/Y TTM	-5.39%	Oper. Margin	-322.00%	RSI (14)	34.52	Volatility	10.44% 10.35%
Employees	140	Debt/Eq	0.16	Sales Y/Y TTM	15.67%	Profit Margin	-284.43%	Recom	1.11	Target Price	11.50
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	-17.18%	Payout	-	Rel Volume	1.52	Prev Close	2.85
Sales Surprise	43.90%	EPS Surprise	26.37%	Sales Q/Q	8.15%	Earnings	Nov 06 BMO	Avg Volume	1.85M	Price	3.06
SMA20	-15.09%	SMA50	-36.92%	SMA200	-60.48%	Trades		Volume	2,799,649	Change	7.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-17-24	Initiated	Jefferies	Buy	$19
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight	$18
Dec-08-23	Initiated	B. Riley Securities	Buy	$16
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Sep-20-21	Initiated	SVB Leerink	Outperform	$25

Dec-03-24 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.14%
Nov-27-24 07:00AM	Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +6.25%
Nov-23-24 10:26AM	Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-06-24 07:05AM	Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (Business Wire) -37.45%
07:00AM	Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program (Business Wire)
07:00AM	Loading…
Aug-28-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-18-24 09:03AM	Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks (TipRanks)
Aug-07-24 07:00AM	Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
Jun-14-24 05:10AM	Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.44%
Jun-05-24 07:00AM	Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-23-24 09:18AM	Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program (PR Newswire)
07:00AM	Tango Therapeutics Announces Discontinuation of TNG348 Program (Business Wire)
May-08-24 01:53PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
10:00AM	Loading…
May-07-24 10:00AM	Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-01-24 04:48PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-20-24 05:31AM	Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-18-24 02:52PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.09%
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-06-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Mar-05-24 04:47PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire)
Jan-31-24 07:00AM	Tango Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-05-24 04:05PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 02:47AM	Medivirs licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study (PR Newswire)
Jan-03-24 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers (GlobeNewswire)
Nov-13-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting (GlobeNewswire) -9.45%
03:12PM	Loading…
Nov-08-23 03:12PM	Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-07-23 07:00AM	Tango Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-10-23 11:28AM	Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why (Zacks)
Oct-09-23 08:50AM	What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing' (Zacks) -13.27%
Sep-18-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.88%
Sep-06-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers (GlobeNewswire)
Sep-05-23 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-29-23 05:08PM	Tango Therapeutics Announces Updates to Its Board of Directors (GlobeNewswire) -7.51%
Aug-28-23 07:00AM	Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer (GlobeNewswire)
Aug-10-23 07:00AM	Tango Therapeutics Announces $80 million Private Placement Financing (GlobeNewswire) -16.26%
Aug-07-23 07:00AM	Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-24-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers (GlobeNewswire)
Jul-10-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors (GlobeNewswire)
Jun-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-23 07:00AM	Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire) +6.40%
Apr-18-23 04:30PM	Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire) -11.67%
Apr-03-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers (GlobeNewswire) +10.38%
Mar-27-23 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -9.35%
Mar-14-23 08:11PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire)
Mar-10-23 10:15PM	Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank (GlobeNewswire) -13.33% +6.45%
Mar-06-23 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development (GlobeNewswire) +6.09%
Feb-02-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-25-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates (GlobeNewswire)
Dec-15-22 07:00AM	HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors (GlobeNewswire)
Nov-10-22 07:00AM	Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -5.27%
Nov-07-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-19-22 07:00AM	Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-05-22 08:10AM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting (GlobeNewswire)
Sep-06-22 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -12.62%
Aug-13-22 08:27AM	The Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts (Simply Wall St.)
Aug-10-22 07:00AM	Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +22.41%
Aug-02-22 07:00AM	Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire) +6.30%
Jun-27-22 07:00AM	Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes (GlobeNewswire)
Jun-20-22 07:26AM	We Think Tango Therapeutics (NASDAQ:TNGX) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-08-22 07:00AM	Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
May-11-22 07:00AM	Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -7.57%
May-09-22 07:00AM	Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022 (GlobeNewswire) -12.62%
Apr-19-22 07:22AM	Shareholders in Tango Therapeutics (NASDAQ:TNGX) are in the red if they invested a year ago (Simply Wall St.)
Mar-28-22 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-08-22 04:57PM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting (GlobeNewswire)
Mar-03-22 09:41AM	Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress (GlobeNewswire) -7.42%
Feb-28-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-24-22 07:00AM	Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates (GlobeNewswire) +5.30%
Jan-11-22 09:37AM	We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow (Simply Wall St.)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com)
Nov-11-21 07:00AM	Tango Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-21 10:42AM	Investors in Tango Therapeutics (NASDAQ:TNGX) have made a return of 24% over the past year (Simply Wall St.)
Nov-09-21 07:00AM	Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-01-21 07:00AM	Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel (GlobeNewswire)
Sep-30-21 04:31PM	Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021 (Business Wire) +7.48%

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rothenberg Mace	Director	Nov 18 '24	Buy	3.78	10,000	37,800	31,250	Nov 18 07:20 PM
Rothenberg Mace	Director	Nov 14 '24	Buy	3.62	10,000	36,200	21,250	Nov 18 07:20 PM
EcoR1 Capital, LLC	10% Owner	Nov 06 '24	Sale	3.28	1,494,558	4,896,023	11,836,178	Nov 08 07:24 PM
EcoR1 Capital, LLC	10% Owner	Nov 07 '24	Sale	2.94	1,205,442	3,539,720	10,630,736	Nov 08 07:24 PM
Boxer Capital Management, LLC		Nov 06 '24	Sale	3.14	3,080,000	9,671,200	3,610,642	Nov 07 09:30 PM
Boxer Capital Management, LLC	Member of group formerly ownin	Nov 06 '24	Proposed Sale	5.18	575,000	2,978,500		Nov 06 09:40 PM
Boxer Capital Management, LLC		Oct 25 '24	Sale	6.87	633,000	4,348,710	6,690,642	Oct 28 06:59 AM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 25 '24	Proposed Sale	6.29	100,000	629,000		Oct 25 09:30 PM
Boxer Capital Management, LLC		Oct 21 '24	Sale	7.05	625,000	4,406,250	7,573,642	Oct 23 09:31 PM
Boxer Capital Management, LLC		Oct 22 '24	Sale	6.78	250,000	1,695,000	7,323,642	Oct 23 09:31 PM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 22 '24	Proposed Sale	7.15	127,600	912,340		Oct 22 08:50 PM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 21 '24	Proposed Sale	7.46	500,000	3,730,000		Oct 22 12:03 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 13 '24	Sale	10.53	67,400	709,756	16,859,075	Sep 17 04:48 PM
Third Rock Ventures IV, L.P.	Affiliate	Sep 13 '24	Proposed Sale	10.50	67,400	707,700		Sep 13 05:43 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '24	Sale	11.56	75,000	867,135	16,926,475	Sep 09 07:19 PM
Third Rock Ventures IV, L.P.	Affiliate	Sep 05 '24	Proposed Sale	11.68	75,000	876,000		Sep 05 05:01 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 30 '24	Sale	11.60	175,000	2,029,702	17,001,475	Sep 04 08:42 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 30 '24	Proposed Sale	11.83	175,000	2,070,250		Aug 30 05:24 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 27 '24	Sale	11.55	25,000	288,665	17,176,475	Aug 29 04:40 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 27 '24	Proposed Sale	11.40	25,000	285,000		Aug 27 04:53 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '24	Sale	10.09	150,000	1,513,920	17,201,475	Aug 20 05:59 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 16 '24	Sale	9.79	135,000	1,321,448	17,351,475	Aug 20 05:59 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 19 '24	Proposed Sale	10.68	150,000	1,602,000		Aug 19 05:35 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 16 '24	Proposed Sale	9.96	135,000	1,344,600		Aug 16 05:14 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 31 '24	Sale	9.93	100,000	993,380	17,526,475	Aug 01 05:51 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 30 '24	Sale	9.80	95,000	931,114	17,626,475	Aug 01 05:51 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 01 '24	Sale	9.80	40,000	392,000	17,486,475	Aug 01 05:51 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 01 '24	Proposed Sale	9.45	40,000	378,000		Aug 01 05:30 PM
Third Rock Ventures IV, L.P.	Affiliate	Jul 31 '24	Proposed Sale	9.85	100,000	985,000		Jul 31 05:32 PM
Third Rock Ventures IV, L.P.	Affiliate	Jul 30 '24	Proposed Sale	9.70	95,000	921,500		Jul 30 05:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 26 '24	Sale	9.84	50,000	491,950	17,721,475	Jul 30 04:15 PM
Third Rock Ventures IV, L.P.	Affiliate	Jul 26 '24	Proposed Sale	9.75	50,000	487,500		Jul 26 05:41 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 24 '24	Sale	9.82	200,000	1,963,160	17,872,074	Jul 26 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 25 '24	Sale	9.87	100,599	992,771	17,771,475	Jul 26 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 22 '24	Sale	9.78	262,740	2,570,096	18,197,074	Jul 24 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 23 '24	Sale	9.79	125,000	1,223,350	18,072,074	Jul 24 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 18 '24	Sale	9.81	191,490	1,878,479	18,459,814	Jul 22 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Jul 17 '24	Sale	9.79	550,171	5,386,339	18,651,304	Jul 18 04:15 PM
MVA Investors, LLC		Jul 01 '24	Sale	8.87	110,731	982,184	203,793	Jul 02 08:56 PM
MVA Investors, LLC		Jul 02 '24	Sale	8.68	95,000	824,600	108,793	Jul 02 08:56 PM
MVA Investors, LLC		Jun 28 '24	Sale	8.57	29,000	248,530	314,524	Jul 02 08:56 PM
MVA Investors, LLC		Jun 07 '24	Sale	6.88	77,000	529,760	343,524	Jun 07 09:14 PM
MVA Investors, LLC		Jun 06 '24	Sale	7.24	63,000	456,120	420,524	Jun 07 09:14 PM
MVA Investors, LLC		May 02 '24	Sale	7.56	75,000	567,000	543,524	May 03 09:34 PM
MVA Investors, LLC		May 01 '24	Sale	7.43	75,000	557,250	618,524	May 03 09:34 PM
MVA Investors, LLC		May 03 '24	Sale	7.61	60,000	456,600	483,524	May 03 09:34 PM
Third Rock Ventures IV, L.P.	10% Owner	Feb 20 '24	Sale	12.00	162,500	1,950,000	19,201,475	Feb 21 05:52 PM
Weber Barbara	Chief Executive Officer	Feb 06 '24	Sale	12.56	4,681	58,806	1,539,624	Feb 08 09:14 PM
Weber Barbara	Chief Executive Officer	Feb 07 '24	Sale	12.62	4,457	56,246	1,535,167	Feb 08 09:14 PM
Barry Douglas	General Counsel	Feb 06 '24	Sale	12.56	1,422	17,864	45,335	Feb 08 09:09 PM
Barry Douglas	General Counsel	Feb 07 '24	Sale	12.62	1,354	17,087	43,981	Feb 08 09:09 PM
Beckman Daniella	Chief Financial Officer	Feb 06 '24	Sale	12.56	1,908	23,969	134,214	Feb 08 09:08 PM
Beckman Daniella	Chief Financial Officer	Feb 07 '24	Sale	12.62	1,817	22,930	132,397	Feb 08 09:08 PM
Crystal Adam	See Remarks	Feb 06 '24	Sale	12.56	4,288	53,868	123,561	Feb 08 09:04 PM
Crystal Adam	See Remarks	Feb 07 '24	Sale	12.62	4,083	51,527	119,478	Feb 08 09:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNGX

Tango Therapeutics Inc

Upgrade your FINVIZ experience